Health · 31 views
Immediate evolocumab after a heart attack improves LDL-cholesterol goals but not early cardiovascular outcomes
Immediate initiation of evolocumab after a heart attack significantly improved low-density lipoprotein cholesterol (LDL-C) goal achievement, but an early reduction in all-cause death or unplanned cardiovascular hospitalization was not…
Summary
Immediate initiation of evolocumab after a heart attack significantly improved low-density lipoprotein cholesterol (LDL-C) goal achievement, but an early reduction in all-cause death or unplanned cardiovascular hospitalization was not observed compared with standard care. These were the main findings of the AMUNDSEN trial presented in a Hot Line session at ESC Congress 2026 and published simultaneously in JAMA . Patients who experience a myocardial infarction (MI) are at particularly high risk of recurrent cardiovascular events, especially within the first year.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedCoverage Context
More from Health
Continue reading recent Health coverage
- IDSA: Earlier introduction of HPV vaccine improves initiation, completion by age 13Continue reading
- The Ebola outbreak is breaking records -- and just marked a grim milestoneContinue reading
- Pathology research identifies potential new target for preventing brain metastasisContinue reading
- Novel HDAC Inhibitor Hits Main Goal in Unresectable Melanoma TrialContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow